BHCM
BEAM icon

Brevan Howard Capital Management’s Beam Therapeutics BEAM Stock Holding History

Brevan Howard Capital Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-49,811
Closed -$1.18M – 1811
2025
Q3 		$1.18M Buy
+49,811
New +$991K 0.01% 823
2021
Q2 		– Sell
-30,000
Closed -$2.4M – 42
2021
Q1 		$2.4M Buy
+30,000
New +$2.85M 0.35% 39

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Brevan Howard Capital Management's BEAM Position: Q4 2025 in Review

Brevan Howard Capital Management sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 49,811 shares — an estimated $1.18M sold.

Brevan Howard Capital Management first reported a position in BEAM in Q1 2021 and held it in 2 quarters. The position peaked at $2.4M in Q1 2021. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Brevan Howard Capital Management reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Brevan Howard Capital Management sold 49,811 Beam Therapeutics shares in Q4 2025, an estimated $1.18M.
  • Brevan Howard Capital Management first reported a position in Beam Therapeutics in Q1 2021 and held it in 2 quarters.
  • Brevan Howard Capital Management's Beam Therapeutics position peaked at $2.4M in Q1 2021.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Brevan Howard Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.